Omicron, a new SARS-CoV-2 variant: assessing the impact on severity and vaccines efficacy새로운 SARS-CoV-2 변종인 Omicron: 중증도 및 백신 효능에 대한 영향 평가Article Published on 2022-12-312022-09-11 Journal: Human vaccines & immunotherapeutics [Category] COVID19(2023년), SARS, 변종, [키워드] Comment COVID-19 COVID-19 vaccine distribution Efficacy India Mild new SARS-CoV-2 omicron rising RT-PCR testing SARS-CoV-2 severity Vaccine vaccine candidate vaccine efficacy vaccine efficacy. Vaccine hesitancy variant variant of SARS-CoV-2 [DOI] 10.1080/21645515.2022.2034458 PMC 바로가기 [Article Type] Article
Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human primatesArticle Published on 2022-12-012022-11-15 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] accompanied Blood clinical investigation Coverage COVID-19 COVID-19 pandemic COVID-19 vaccine cytokine release Diseases effective effort elicit Gam-COVID-Vac Health heterologous prime-boost IgA antibody IgG immune response Immunity immunization immunogenic immunogenicity Infection intranasal intranasal vaccine. intranasally K18-hACE2 transgenic mice less lung immunopathology mice mononuclear cell Mortality mucosal nasal mucosa neutralizing antibody non-human primate pandemic Peripheral blood Prevent proliferation protective immunity provided revaccination robust SARS-CoV-2 SARS-COV-2 infection SARSCoV-2 serum Sputnik V systemic and local the vaccine Transmission vaccination Vaccination strategy Vaccine vaccine candidate variants of concern virus virus infection virus spread [DOI] 10.1080/22221751.2022.2119169 PMC 바로가기
Peptide microarrays coupled to machine learning reveal individual epitopes from human antibody responses with neutralizing capabilities against SARS-CoV-2기계 학습과 결합된 펩티드 마이크로어레이는 SARS-CoV-2에 대한 중화 기능을 가진 인간 항체 반응의 개별 에피토프를 나타냅니다.Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 진단, 치료기술, 치료법, [키워드] anti-SARS-CoV-2 antibody Antibody binding assays binding epitope capture causative agent cellular coronavirus coronavirus SARS-CoV-2 Course COVID-19 detectable epitope Epitopes human antibody response IgA IgG IgM antibody immunoassays incubated infected with SARS-CoV-2 machine learning Microarray N-terminus negative control samples neutralization neutralization assays Neutralizing Neutralizing antibodies nine overlapping Patient peptide peptide arrays peptides positive protective effect Protective effects random Random forest response S protein SARS CoV SARS CoV-2 SARS-CoV-2 sera serology Serology. Specific structural protein structural proteins the disease the S protein vaccine candidate vaccine candidates Viral [DOI] 10.1080/22221751.2022.2057874 PMC 바로가기 [Article Type] Article
Intranasal nanoemulsion adjuvanted S-2P vaccine demonstrates protection in hamsters and induces systemic, cell-mediated and mucosal immunity in miceArticle Published on 2022-11-022022-11-15 Journal: PLoS ONE [Category] SARS, 변종, 진단, [키워드] Activation Arm cellular COVID-19 disease demonstrated development disease Efficacy hamster humoral IgA immune Immunity immunization induce intramuscular intramuscularly intranasal intranasally Lower respiratory tract lung Lung pathology medical need memory B cell mice mucosal mucosal immune pandemic promote protective immunity public health rapid progress response resulting robust S-2P Safe SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccine Seroconversion Spike protein systemic immune response the SARS-CoV-2 Transmission unique upper respiratory tract Vaccine vaccine candidate variants viral clearance weight loss while [DOI] 10.1371/journal.pone.0272594 PMC 바로가기
A triple-RBD-based mucosal vaccine provides broad protection against SARS-CoV-2 variants of concernArticle Published on 2022-11-012022-11-15 Journal: Cellular and Molecular Immunology [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] antibodies antigenic chimeric correlated Delta effective elicit flagellin Flagellin adjuvant human ACE2 IgA immunization Infection initial intranasal intranasal immunization Lower lung mucosal mucosal vaccine Mutation nasal neutralizing antibody neutralizing immunity omicron pathology Protein provide RBD reduce SARS-CoV-2 SARS-CoV-2 variant secretory IgA significantly specificity Spread tissue pathology transgenic mice transmission potential Triple-RBD Vaccine vaccine candidate variant Variant of concern. Viral RNA [DOI] 10.1038/s41423-022-00929-3 PMC 바로가기
A subunit vaccine candidate based on the Spike protein of SARS-CoV-2 prevents infectious virus shedding in catsSARS-CoV-2의 스파이크 단백질을 기반으로 하는 서브유닛 백신 후보는 고양이의 감염성 바이러스 발산을 방지합니다Article Published on 2022-11-012022-09-11 Journal: Research in veterinary science [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] affected cats demonstrated described effective human infection Infection Infectious virus Neutralizing antibody response occurred Oropharyngeal Population Prevent preventive measure preventive measures produced Protein rectal swab SARS-CoV-2 SARS-CoV-2 virus spike Spike protein submitted subunit Subunit vaccine Subunit vaccine. susceptible the disease the SARS-CoV-2 virus the Spike Transmission Trial triggered vaccination Vaccine vaccine candidate Viral viral infection virus [DOI] 10.1016/j.rvsc.2022.05.003 PMC 바로가기 [Article Type] Article
High Neutralizing Antibody Levels Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.1 and BA.2 After UB-612 Vaccine BoosterArticle Published on 2022-10-172022-11-15 Journal: The Journal of Infectious Diseases [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] acute respiratory syndrome Against binding antibody booster booster dose Breakthrough infection caused clinical trial coronavirus coronavirus 2 coronavirus disease COVID-19 Efficacy Level Neutralizing neutralizing antibody omicron Protein Receptor-binding domain respiratory responses SARS-CoV-2 SARS-CoV-2 variants subunit Support symptomatic the receptor-binding domain vaccination Vaccine vaccine candidate Vaccines variant Variant. variants [DOI] 10.1093/infdis/jiac241 PMC 바로가기
Serum angiotensin-converting enzyme 2 as a potential biomarker for SARS-CoV-2 infection and vaccine efficacyArticle Published on 2022-10-122022-11-15 Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 바이오마커, [키워드] ACE2 angiotensin-converting enzyme 2 Biomarker change changes in circulating cleaved COVID-19 death declined demonstrated Disease progression dose Efficacy elevated expressing full-length highlight host cell receptor human ACE2 humans immunization increase in K18-hACE2 mice membrane mice MVA-S vaccine prevented Proteolytic processing receptor SARS-CoV-2 SARS-COV-2 infection serum serum sample serum. subsequent susceptible the SARS-CoV-2 transgenic vaccination Vaccine vaccine candidate virus virus entry [DOI] 10.3389/fimmu.2022.1001951 PMC 바로가기
Accelerating model-informed decisions for COVID-19 vaccine candidates using a model-based meta-analysis approachArticle Published on 2022-10-012022-11-15 Journal: EBioMedicine [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] Analysis applied approach calibrated candidate carried clinical Clinical efficacy clinical trial convalescent CoronaVac COVID-19 COVID-19 pandemic COVID-19 vaccine develop Efficacy humans immunogenicity data Inc. joint literature review LLC Meta-analysis Model-based meta-analysis (MBMA) modelling Modelling and simulation Neutralizing predict predicted Predictive Predictive model Quantitative reported rhesus macaque Safe SARS-CoV-2 SARS-CoV-2 vaccines serum Sharp strain Study design Support systematic literature search the mean titre translation translational USA vaccination Vaccine vaccine candidate Vaccines. variant Viral load were used [DOI] 10.1016/j.ebiom.2022.104264 PMC 바로가기
Current clinical status of new COVID-19 vaccines and immunotherapyArticle Published on 2022-10-012022-11-16 Journal: Environmental science and pollution research inter [Category] COVID19(2023년), SARS, 변종, [키워드] affected antiviral drugs approval caused Children vaccine clinical clinical outcomes clinical status clinical study clinical trial Coronaviridae family COVID-19 covid-19 therapies COVID-19 vaccine current death develop Efficacy expected healthcare worker help human clinical trial Immunotherapy Impact Initially management MERS Nano vaccine pandemic RNA SARS-CoV-2 the WHO therapy treatment approach US-FDA vaccination Vaccine vaccine candidate Vaccine development vaccine. variant Wuhan, China [DOI] 10.1007/s11356-022-22661-1 PMC 바로가기